Is CSL Limited (CSLLY) a Buy, Sell, or Hold?
OTC : CSLLY
CSL Limited — News
$23.735 USD
$0.22 (0.94%)
- Volume
- 7.63K
- Average Volume
- 436.7K
- Market Capitalization
- $91.91B
- P/E Ratio
- 31.85
- Dividend Yield
- 3.17%
- Price Target
- $153.50
- Year High
- $44.78
- Year Low
- $16.01
- Day High
- —
- Day Low
- —
- Payout Ratio
- $1.03
- Current Ratio
- $2.57
| Source | Headline |
|---|---|
|
CSL Q2 Earnings Beat Estimates on Record Sales, Outlook Raised
Carlisle tops Q2 earnings and revenue estimates, posts record sales and raises its 2026 outlook as organic growth supported both reporting segments. zacks.com - 2026-07-30 12:41:12 |
|
CSL to start clinical trials for new immunoglobulin manufacturing process
Australian biotechnology firm CSL said on Wednesday it would start clinical trials to support regulatory approval for a new manufacturing process aimed at lifting immunoglobulin output from the same amount of plasma. reuters.com - 2026-07-28 21:00:18 |
|
CSL Reports Positive Top-Line Phase 3b Results Supporting Planned Expanded Pediatric Filing for ANDEMBRY® (garadacimab-gxii) in Children with Hereditary Angioedema (HAE)
CSL plans to begin submitting regulatory filings for expanded pediatric indication for ANDEMBRY in the first half of the company's fiscal year Full data to be presented at upcoming scientific congress KING OF PRUSSIA, Pa., July 27, 2026 /PRNewswire/ -- Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) today announced positive top-line Phase 3b results evaluating ANDEMBRY® (garadacimab-gxii) in children aged 2 to 11 years with hereditary angioedema (HAE). prnewswire.com - 2026-07-27 09:00:00 |
|
CHMP recommends revoking marketing authorisation for TAVNEOS® (avacopan) in the European Union
Recommendation follows an Article 20 non-pharmacovigilance procedure Patients currently on TAVNEOS treatment should consult their treating physician ST. GALLEN, Switzerland, June 26, 2026 /PRNewswire/ -- Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and CSL announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the revocation of the European Union (EU) marketing authorisation for TAVNEOS® (avacopan). prnewswire.com - 2026-06-26 09:00:00 |
|
CSL Delivers World's First Battery-Powered Self-Unloading Bulk Carrier to Support Adbri Operations
SYDNEY, June 12, 2026 (GLOBE NEWSWIRE) -- The CSL Group (“CSL”), a global leader in responsible marine transportation services, and Adbri announce the delivery of MV Yampu, the world's first battery-powered self-unloading bulk carrier. The vessel was officially delivered at Jiangjiang Nanyang Shipyard on June 5, 2026, and has now departed on its maiden voyage to commence operations for Adbri in Birkenhead, South Australia. globenewswire.com - 2026-06-12 12:35:00 |
|
Australia says CSL unit Seqirus to discontinue Benpen injections from November
Australia's drug regulator said on Wednesday it was notified by biopharmaceutical giant CSL's unit Seqirus that it will be discontinuing all strengths of their Benpen injection products progressively due to commercial reasons. reuters.com - 2026-05-27 03:20:38 |
|
CSL Limited (CSLLY) Shareholder/Analyst Call Transcript
CSL Limited (CSLLY) Shareholder/Analyst Call Transcript seekingalpha.com - 2026-05-14 15:30:47 |
